Trial Profile
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RNS 60 (Primary) ; RNS 60 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 04 Jan 2019 According to a Revalesio media release, results of this study were published in the journal Muscle & Nerve.
- 05 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.